Skip to the beginning of the images gallery

Add to Wish List

Camrelizumab Biosimilar - Research Grade

Name: Camrelizumab Biosimilar - Research Grade
SKU: ICH5003
Price: 315 USD
Availability: InStock

In stock

Only %1 left

SKU

ICH5003

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Camrelizumab Biosimilar - Research Grade

Endotoxin

<1 EU/mg Determined by LAL gel clotting assay

Purity

>95% by SDS-PAGE and HPLC

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

Human IgG4

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of the anti-PD-1 antibody camrelizumab, supplied for research use only. It is a human IgG4 format antibody directed against human PD-1 (PDCD1, UniProt Q15116) and is intended to reproduce the target-binding behaviour of the originator molecule so researchers can use it as a well-defined reference reagent rather than as a clinical drug. Because it recapitulates PD-1 engagement, it is useful as a positive control in binding and blocking assays, as a benchmarking tool against other anti-PD-1 reagents, and as a building block for ADCC/ADC and engineered-format development work. It is produced at research grade with low endotoxin (typically less than 1 EU/mg, with ultra-low-endotoxin lots under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support in-vitro and preclinical workflows. It is not the clinical product and is not intended for human or veterinary use. The IgG4 backbone limits Fc effector engagement, consistent with a checkpoint-blocking design. PD-1 (programmed cell death protein 1; gene PDCD1; UniProt Q15116) is a type I transmembrane immunoinhibitory receptor of the CD28/B7 family, expressed on activated T cells and also on B cells, NK cells, and some myeloid populations. Its cytoplasmic tail carries an ITIM and an ITSM motif; upon engagement by its ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2), PD-1 recruits the phosphatase SHP-2, which dephosphorylates proximal T-cell receptor and CD28 signalling components, dampening T-cell activation, proliferation, and cytokine output. This pathway maintains peripheral tolerance and limits immunopathology, but tumours and chronically infected tissues exploit it to drive T-cell exhaustion. Antibodies that block the PD-1/PD-L1 axis restore effector T-cell function, the mechanistic basis of checkpoint-blockade immunotherapy.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Camrelizumab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Write Your Own Review

You're reviewing:Camrelizumab Biosimilar - Research Grade

Your Rating

Rating